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Abstract
Background. In 2016, the World Health Organization reclassified the definition of glioblastoma (GBM), dividing 
these tumors into isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant GBM, where the vast majority of 
GBMs are IDH-wild-type. Nomograms are useful tools for individualized estimation of survival. This study aimed to 
develop and independently validate a nomogram for IDH-wild-type patients with newly diagnosed GBM.
Methods. Data were obtained from newly diagnosed GBM patients from the Ohio Brain Tumor Study (OBTS) and 
the University of California San Francisco (UCSF) for diagnosis years 2007–2017 with the following variables: age at 
diagnosis, sex, extent of resection, concurrent radiation/temozolomide (TMZ) status, Karnofsky Performance Status 
(KPS), O6-methylguanine-DNA methyltransferase (MGMT) methylation status, and IDH mutation status. Survival 
was assessed using Cox proportional hazards regression, random survival forests, and recursive partitioning anal-
ysis, with adjustment for known prognostic factors. The models were developed using the OBTS data and inde-
pendently validated using the UCSF data. Models were internally validated using 10-fold cross-validation and 
externally validated by plotting calibration curves.
Results. A final nomogram was validated for IDH-wild-type newly diagnosed GBM. Factors that increased the 
probability of survival included younger age at diagnosis, female sex, having gross total resection, having concur-
rent radiation/TMZ, having a high KPS, and having MGMT methylation.
Conclusions. A nomogram that calculates individualized survival probabilities for IDH-wild-type patients with 
newly diagnosed GBM could be useful to physicians for counseling patients regarding treatment decisions and 
optimizing therapeutic approaches. Free software for implementing this nomogram is provided: https://gcioffi.
shinyapps.io/Nomogram_For_IDH_Wildtype_GBM_H_Gittleman/.
Key Points
1. A nomogram for IDH-wild-type glioblastoma patients has been developed and externally 
validated.
2. Free software for implementing this nomogram is provided allowing for the ease of use 
by practicing healthcare providers.
An independently validated nomogram for isocitrate 
dehydrogenase-wild-type glioblastoma patient survival
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Glioblastoma (GBM) is the most common malignant brain 
and other central nervous system tumor, comprising 14.7% 
of all primary brain tumors, 47.7% of all malignant brain 
tumors, and 56.6% of all gliomas in the United States.1–14 
Patients with GBM have poor prognosis, with a 5-year rel-
ative survival rate of 5.6% and median overall survival 
of 12–15  months.1–8,15,16 Prognostic factors include age, 
sex, extent of surgical resection, treatment, Karnofsky 
performance status (KPS), and race, as well as certain 
bio markers.1–3,9,15,17 These biomarkers include methylation 
status of the gene promoter for O6-methylguanine-DNA 
methyltransferase (MGMT) and isocitrate dehydrogenase 
enzyme 1/2 (IDH1/2) mutation.1,2,4,18–20 In 2016, the World 
Health Organization (WHO) reclassified the definition of 
GBM, dividing these tumors into IDH-wild-type and IDH-
mutant GBM.18 IDH mutations are rare in GBM, accounting 
for less than 10% of patients with GBM.4,19 The current 
standard of care for GBM consists of maximal safe sur-
gical resection followed by radiotherapy with concurrent 
temozolomide (TMZ) chemotherapy, sometimes followed 
by adjuvant TMZ.1,2,5,9–11,16,17,19,21
Nomograms are accessible tools for physicians to use on 
behalf of their patients for predicting survival, developing 
an individualized cancer prognosis valuable for treatment 
decision-making, and deciding the interval for follow-up 
and/or imaging.22 Two nomograms have been developed 
previously for GBM. The first used data from a European 
Organisation for Research and Treatment of Cancer-
National Cancer Institute of Canada (EORTC-NCIC) clinical 
trial (EORTC 26981/22981-NCIC); however, this nomogram 
was only internally validated.23 The second, developed by 
our team, used data from 2 independent, nonoverlapping 
NRG Oncology Radiation Therapy Oncology Group clinical 
trials, 0525 and 0825.22 Although this GBM nomogram was 
both internally and externally validated, it did not include 
some important prognostic factors, such as whether or not 
the patient received concurrent radiation/TMZ and IDH mu-
tation status.
Because of the 2016 WHO redefinition of GBM, the pur-
pose of this study was to develop and independently val-
idate a nomogram for the estimation of individualized 
survival probabilities for newly diagnosed IDH-wild-type 
GBM patients that would be easy to use through an online 
interface. The final nomogram was created using data 
from the Ohio Brain Tumor Study (OBTS) and externally 
validated using data from the University of California San 
Francisco (UCSF).
Materials and Methods
Data Collection and Study Population
This study was approved by the University Hospitals and 
UCSF Institutional Review Boards. De-identified data were 
provided by the OBTS and the UCSF for the diagnosis years 
2007–2017 on newly diagnosed GBM patients who were at 
least 18 years of age at diagnosis. GBM was defined using 
ICD-O-3 codes 9440/3, 9441/3, and 9442/3. The OBTS data ini-
tially included 218 newly diagnosed GBM patients, whereas 
the UCSF data initially included 128 newly diagnosed GBM 
patients. The following variables were obtained for each pa-
tient: age at diagnosis (continuous), sex (male or female), 
race (white, black, or other), extent of surgical resection (bi-
opsy, subtotal resection, gross total resection; gross total 
resection defined as >98% of the enhancing region of the 
tumor resected when comparing pre- vs postoperative 
MRI), KPS (10–100 in tens) recorded postsurgery, concur-
rent radiation/TMZ (yes or no), IDH1 mutation (yes or no), 
MGMT methylation (yes or no), survival/follow-up time in 
months (continuous), and survival status (alive or dead). 
Because of the small sample of patients with low values 
for KPS, this variable was dichotomized into at least 70 and 
less than 70. Because the UCSF data only included patients 
who had subtotal or gross total surgical resection, patients 
who had biopsy only were dropped from the OBTS data, 
leaving a total of 200 patients left in the OBTS dataset. 
Missing data were imputed using multivariate imputa-
tion by chained equations using the R package “mice.”24 
The raw, unimputed data for the 2 datasets are displayed 
in Supplementary Table 1. After data were imputed, IDH1-
mutant patients (21 in OBTS and 6 in UCSF) were removed. 
The final OBTS dataset had a total of 179 patients, and the 
final UCSF dataset had a total of 122 patients, both sets 
only including patients with IDH-wild-type tumors.
Importance of the Study
Glioblastoma (GBM) is the most common ma-
lignant brain tumor. In 2016, the World Health 
Organization reclassified the definition of GBM, 
dividing these tumors into isocitrate dehydro-
genase (IDH)-wild-type and IDH-mutant GBM, 
where the vast majority of GBMs are IDH-wild-
type. A nomogram accounts for several prog-
nostic factors and is an easily accessible tool for 
physicians to use on behalf of their patients for 
predicting survival, developing individualized 
cancer prognosis, and deciding the interval 
for follow-up and/or imaging. A  nomogram 
for assessing survival estimates for IDH-wild-
type patients with GBM has been developed 
and independently validated. To facilitate clin-
ical use of this nomogram, free software for 
its implementation is provided (https://gcioffi.
shinyapps.io/Nomogram_For_IDH_Wildtype_
GBM_H_Gittleman/). The nomogram provides 
an individualized estimate of survival rather 
than a group estimate. This tool can be useful 
to patients and healthcare providers for coun-
seling patients and their families regarding 
treatment decisions, follow-up, and prognosis.
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All GBMs were histologically confirmed. IDH testing 
was conducted via immunohistochemistry and reviewed 
at each participating center by an expert neuropatholo-
gist. MGMT methylation testing was performed using a 
standard pyrosequencing approach where purified ge-
nomic DNA was treated with sodium bisulfite to convert 
unmethylated cytosines into uracil. After conversion, a 
targeted region was amplified by polymerase chain reac-
tion. Methylation of 5 CpG islands in an MGMT promoter 
region was analyzed by pyrosequencing using Qiagen 
PyroMark Q96ID (Qiagen, Germany). Percentage of methyl-
ation of each CpG island was analyzed and a percent mean 
of MGMT methylation is reported. Percent mean methyla-
tion 10% or greater was considered positive.
Statistical Analyses
Descriptive statistics were used to assess any differences 
in patient characteristics and prognostic factors between 
the 2 datasets using t-tests for continuous variables and 
chi-square tests for categorical variables in the unimputed 
and imputed datasets. Using the “survival” package in R25, 
overall survival, as well as adjusted survival by age at diag-
nosis and KPS, were calculated for each of the 2 datasets 
using the Kaplan–Meier method, and differences were 
assessed using the log-rank test. Adjusting for age at di-
agnosis, sex, extent of surgical resection, concurrent ra-
diation/TMZ, KPS, and MGMT methylation status, overall 
survival was assessed using Cox proportional hazards 
(CPH) regression (“survival” package),25 random survival 
forests (RSF) (“randomForestSRC” package),26 and recur-
sive partitioning analysis (RPA) (“rpart” package).27 In CPH, 
the proportional hazards assumption was verified using 
the methodology by Grambsch and Therneau.28 In RSF, an 
ensemble tree method for analyzing right-censored sur-
vival data was used to generate 1000 trees, and all pos-
sible split points for each variable were evaluated to find 
the optimal split solution. In RPA, a full recursive classifica-
tion tree was generated and the least important splits were 
removed recursively to obtain the final subclassification 
tree with the minimal model deviance.
The models were trained using the OBTS data and in-
dependently, externally validated using the UCSF data. 
Models were also internally validated using 10-fold cross-
validation, and individual predicted 12-, 18-, and 24-month 
survival probabilities were generated to measure predic-
tive accuracy compared with the observed survival as 
“ground truth.” The predictive accuracies for overall sur-
vival of the 3 statistical approaches (CPH, RSF, and RPA) 
were calculated using the concordance index, which 
ranges from 0.5 (completely random prediction) to 1 (per-
fect prediction) and is equivalent to the area under the re-
ceiver operating characteristic curve for censored data.29 
A final nomogram was developed using the method with 
the greatest predictive accuracy for individualized estima-
tion of survival. Calibration of the final model was visually 
examined by assigning all patients into quintiles of the 
nomogram-predicted 12-month survival probabilities and 
plotting the mean nomogram predicted 12-month survival 
probability against the Kaplan–Meier estimated 12-month 
survival for each quintile using the “rms” R package.30 All 
analyses were performed using R version 3.5.2.31 P-values 
less than .05 were considered to be statistically significant.
Results
Patient Characteristics
Patient demographics for the imputed, IDH-wild-type 
OBTS patients (N = 179) and the UCSF patients (N = 122) 
are presented in Table 1. There were several statistically 
significant differences between the training (OBTS) and 
validation (UCSF) datasets. More patients (59.8%) in the 
OBTS set had gross total surgical resection, whereas 
more patients (62.3%) in the UCSF set had subtotal sur-
gical resection (P < .001). More patients (79.5%) in the 
UCSF set had concurrent radiation/TMZ compared with 
those in the OBTS set (65.9%;P =  .015). Overall, 67.0% of 
OBTS patients had a KPS greater or equal to 70 compared 
with 86.9% of UCSF patients (P < .001). Finally, a greater 
proportion of patients died in the OBTS dataset (91.1%) 
compared with the UCSF dataset (74.6%;P < .001). Patients 
in the OBTS dataset were also older at diagnosis (mean 
age = 63.02 years) than patients in the UCSF dataset (mean 
age = 60.90 years), though this was not significantly dif-
ferent (P = .104).
Survival by the Kaplan–Meier Method and CPH
Without adjusting for covariates, the Kaplan–Meier curve 
(Figure 1A) showed a significant difference (P =  .026) be-
tween the OBTS and UCSF datasets, with the OBTS 
patients (median survival = 12.3 months; 95% confidence 
interval [CI]: 10.1–13.3 months) having worse survival than 
the UCSF patients (median survival  =  15.2  months; 95% 
CI: 12.9–17.5 months). However, after adjusting for age at 
diagnosis and KPS (Figure 1B), this significant difference 
disappeared (P = .306). The median overall survival for the 
OBTS patients was 12.4 months (95% CI: 10.9–13.3 months), 
and the median overall survival for the UCSF patients was 
13.6 months (95% CI: 12.1–16.2 months). Univariable and 
multivariable CPH regression results are displayed in 
Supplementary Table 2 and Table 2, respectively, for both 
the training set (OBTS) and the validation set (UCSF), dis-
played separately. In the multivariable analyses, younger 
age at diagnosis, having concurrent radiation/TMZ, having 
a KPS of 70 or greater, and having MGMT methylation were 
significantly associated with better survival outcomes (all 
Ps < .05) in both datasets. Being male was significantly as-
sociated with worse survival (P = .011) in the OBTS dataset, 
but not in the UCSF dataset (P =  .402). There was no sig-
nificant difference between having gross total surgical re-
section versus subtotal surgical resection in either of the 
datasets. The data did not violate the proportional hazards 
assumption of the CPH model.
Internal Cross-Validation
After 10-fold cross-validation was performed on the 
training set (OBTS), the concordance indices were 
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computed for each statistical method for predicting sur-
vival at 3 time points: 12, 18, and 24 months (Table 3). For 
all 3 time points, the CPH analysis (12 , 18, 24  months: 
0.756, 0.757, 0.759) outperformed RSF (12, 18, 24 months: 
0.752, 0.740, 0.708) and RPA (12, 18, 24 months: 0.747, 0.747, 
0.747). On the basis of these results, the multivariable CPH 
model was then independently validated using the UCSF 
dataset.
Nomogram and Independent Validation
The nomogram to estimate 12-, 18-, and 24-month sur-
vival probabilities was built using the training dataset 
(OBTS) and validated on the independent dataset (UCSF) 
using the CPH model (Figure 2). An online calculator 
for the final nomogram is available via an internet inter-
face at https://gcioffi.shinyapps.io/Nomogram_For_IDH_
Wildtype_GBM_H_Gittleman/. The final CPH model was 
well calibrated with a concordance index of 0.756 (95% 
CI: 0.719–0.793) in the training dataset. For each quin-
tile group, the estimated versus observed 12-month sur-
vival probabilities intersected the 45° line, indicating that 
the predicted value approximated the observed value 
within a 95% CI (Supplementary Figure 1). Calibration 
curves were also drawn for the training dataset (OBTS) 
for predicted 12-, 18-, and 24-month survival, as well as 
for the independent validation dataset (UCSF) for a visual 
comparison. In Figure 3, the black line shows the observed 
survival rates, the gray line shows the ideal survival rates, 
and the dark gray line shows the optimism-corrected sur-
vival rates. The optimism-corrected (also known as bias-
corrected or overfitting-corrected) line is produced using 
a bootstrap approach to estimate predicted and observed 
values based on a nonparametric smoother applied to a 
sequence of predicted values. For the predicted 12-month 
survival plots (Figure 3A and D), all 3 lines are closely 
aligned, demonstrating good calibration. For the predicted 
18-month survival plots (Figure 3B and E), the observed 
and the ideal 45° lines are well aligned, although the 
optimism-corrected line strays somewhat from the others. 
For the predicted 24-month survival plots (Figures 3C and 
F), the observed and optimism-corrected lines are well-
aligned, although both of these lines stray from the ideal 
45° line, showing some overconfidence.
Discussion
The goal of this study was to develop and validate, both 
internally and externally, an individual survival nomo-
gram for patients with newly diagnosed IDH-wild-type 
GBM. The multivariable CPH regression model had the 
best fit, with high values for the concordance indices at 12, 
18, and 24 -months (all concordance indices > 0.75). This 
  
Table 1.  Isocitrate Dehydrogenase-Wild-Type Newly Diagnosed Primary Glioblastoma Patient Characteristics Using Imputed Data; the Ohio Brain 
Tumor Study (OBTS) and the University of California San Francisco (UCSF), 2007–2017
OBTS (training set) (N = 179) UCSF (validation set) (N = 122) P-value
Age at diagnosis (mean (SD)) [Range] 63.02 (10.98) [29–88] 60.90 (11.28) [24–85] .104
Sex (N (%)) .180
 Male 119 (66.5) 71 (58.2)
 Female 60 (33.5) 51 (41.8)
Surgery status (N (%)) <.001
 Subtotal resection 72 (40.2) 76 (62.3)
 Gross total resection 107 (59.8) 46 (37.7)
Concurrent radiation/TMZ (N (%)) .015
 Yes 118 (65.9) 97 (79.5)
 No 61 (34.1) 25 (20.5)
KPS (N (%)) <.001
 <70 59 (33.0) 16 (13.1)
 ≥70 120 (67.0) 106 (86.9)
MGMT methylation (N (%)) .745
 Yes 79 (44.1) 57 (46.7)
 No 100 (55.9) 65 (53.3)
Follow-up months (median [IQR]) 12.07 
[5.71, 19.75]
13.59 
[7.79, 19.19]
.128
Survival status (N (%)) <.001
 Alive 16 (8.9) 31 (25.4)
 Dead 163 (91.1) 91 (74.6)
IQR = interquartile range; TMZ = temozolomide.
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CPH survival model adjusted for age at diagnosis, sex, 
surgical resection, concurrent radiation/TMZ, KPS, and 
MGMT methylation status, and was then independently, 
externally validated on the UCSF dataset.
Our previous nomogram on all newly diagnosed GBM 
patients regardless of IDH mutation status included age at 
diagnosis, sex, KPS, surgical resection, and MGMT meth-
ylation status.22 We built on this nomogram by subsetting 
to IDH-wild-type patients only, and adding other impor-
tant prognostic variables such as concurrent radiation/
TMZ.1,2,5,9–11,16,17,19,21 Even with these differences, the 2 
nomograms share some similarities. For example, the 
difference between having gross total surgical resection 
and subtotal surgical resection, as well as the difference 
between having methylated versus unmethylated MGMT, 
earned approximately the same amount of points on both 
nomograms.22 The current nomogram found male sex to 
be a more severe marker of worse survival than the older 
nomogram.22 KPS cannot be compared because the cur-
rent nomogram dichotomized this variable (≥70 compared 
with <70), whereas the older nomogram only included 
patients who had a KPS of 70 or higher.22 It is important to 
note that the older nomogram was developed using clin-
ical trial data (training N = 799; validation N = 555)22 and 
therefore had a more robust sample size than that of the 
current study (training N = 179; validation N = 122).
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Fig. 1 Kaplan–Meier survival curves for isocitrate dehydrogenase-wild-type newly diagnosed glioblastoma patients from the Ohio Brain Tumor 
Study and the University of California San Francisco, 2007–2017 (A) unadjusted and (B) adjusted for age at diagnosis and Karnofsky Performance 
Status.
  
  
Table 2.  Multivariable Cox Proportional Hazards Models for Isocitrate Dehydrogenase-Wild-Type Newly Diagnosed Glioblastoma Patients From 
the Ohio Brain Tumor Study (OBTS) and the University of California San Francisco (UCSF), 2007–2017
OBTS (Training; N = 179) UCSF (Validation; N = 122)
Factor HR 95% CI P-value HR 95% CI P-value
Age 1.018 (1.002–1.034) .026 1.025 (1.005–1.045) .016
Sex (male vs female) 1.596 (1.114–2.285) .011 1.206 (0.778–1.870) .402
Surgery (STR vs GTR) 1.084 (0.788–1.493) .620 1.011 (0.634–1.611) .965
Concurrent radiation/TMZ (yes vs. no) 0.244 (0.161–0.369) <.001 0.504 (0.301–0.845) .009
KPS (≥70 vs. <70) 0.351 (0.237–0.520) <.001 0.308 (0.163–0.583) <.001
MGMT methylation (yes vs. no) 0.579 (0.395–0.848) .005 0.474 (0.299–0.764) .002
CI = confidence interval; GTR = gross total resection; HR = hazard ratio; KPS = Karnofsky Performance Status; MGMT = O6-methylguanine-DNA 
methyltransferase; STR = subtotal resection; TMZ = temozolomide.
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IDH mutations define a distinct subset of GBM with 
a favorable outcome.1,4,19,20 These mutations are more 
common in lower grade gliomas such as grade II and 
grade III astrocytomas and oligodendrogliomas, than in 
GBM.1,4,19 Survival of GBM patients with such IDH-mutated 
tumors is more favorable than for nonmutated grade II 
astrocytoma, emphasizing the strong prognostic value 
of this marker.19 Because of the WHO 2016 reclassifica-
tion of the definition of GBM into IDH-wild-type and IDH-
mutant GBM,18 nomograms for GBM patients should be 
developed separately for these 2 unique entities. Because 
more than 90% of the mutations involve IDH1 rather than 
IDH21,19, our subset of IDH-wild-type patients is defined by 
the IDH1 marker. Future work could include developing 
and validating a nomogram for IDH-mutant GBM patients.
There are several limitations to this study. First, the OBTS 
and UCSF datasets had several differences in their pa-
tient populations. The UCSF validation set had a younger, 
healthier patient population than that of OBTS. Treatment 
patterns varied as well, with more patients in the OBTS 
set having had gross total surgical resection and more 
patients in the UCSF set having had subtotal surgical re-
section, and more patients in the UCSF set having had con-
current radiation/TMZ than those in the OBTS set. Patients 
in the UCSF set had better overall survival compared 
with patients in the OBTS set; however, this difference 
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Fig. 2 Validated nomogram for predicted 12-, 18-, and 24-month survival for newly diagnosed isocitrate dehydrogenase-wild-type glioblastoma 
patients; the Ohio Brain Tumor Study, 2007–2017.
  
  
Table 3.  Concordance Indices and Corresponding 95% Confidence Intervals for Cox Proportional Hazards (CPH), Random Survival Forests (RSF), 
and Recursive Partitioning Analysis (RPA) at 12, 18, and 24 Months for Isocitrate Dehydrogenase-Wild-Type Newly Diagnosed Glioblastoma Patients; 
the Ohio Brain Tumor Study (Training Set), 2007–2017
CPH RSF RPA
12 Months 0.756 (0.719–0.793) 0.752 (0.715–0.788) 0.747 (0.710–0.784)
18 Months 0.757 (0.721–0.794) 0.740 (0.704–0.776) 0.747 (0.710–0.784)
24 Months 0.759 (0.722–0.795) 0.708 (0.667–0.749) 0.747 (0.710–0.784)
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disappeared after adjusting for age at diagnosis and KPS. 
Second, because the nomogram was trained from an Ohio 
population and validated on patients from California, both 
of which include world-class tertiary referral centers, the 
results may not be generalizable to patients treated at 
community hospitals. Third, although race was collected 
on patients in both datasets, nearly all of the patients were 
white (91.1% in the OBTS set and 94.2% in the UCSF set). 
Therefore, race was not found to be a significant factor 
and was dropped from the survival models, despite evi-
dence for differences in survival by race in other studies.1,4 
Fourth, because all the patients in the UCSF set had ei-
ther subtotal or gross total surgical resection, biopsy-only 
patients were removed from the OBTS set before analysis. 
Thus, the nomogram may not be predictive for biopsy-
only GBM patients. Fifth, although the OBTS set collected 
data on whether or not patients received adjuvant TMZ, the 
UCSF set did not collect this variable, so this variable was 
not used in the nomogram. Future work could include this 
adjuvant TMZ variable. Sixth, there was a small amount of 
missing data in some of the variables including concur-
rent radiation/TMZ, and a larger amount of missing data 
in KPS, MGMT methylation, and IDH1 mutation status. 
Although missing data were imputed using multivariate 
imputation by chained equations, creating 20 imputed 
datasets, which were pooled together into 1 final complete 
dataset, it is possible to have some level of inaccuracy in 
the imputed values. Because the missing values were de-
rived from other clinical variables in the dataset, variables 
with missing data such as KPS and MGMT may be some-
what reliant on age or other clinical factors. Finally, al-
though the internal and external calibration plots yielded 
nearly perfect calibration at 12 months and good calibra-
tion at 18 months, the observed and optimism-corrected 
lines deviated somewhat from the ideal line in both the 
internal and external validation at 24 months. This could 
be due to relatively small sample sizes in the training and 
validation datasets, which become smaller in 10-fold cross-
validation. Caution should be used in the interpretation of 
the nomogram when analyzing patients with an unusual 
combination of clinical characteristics, as these patients 
may not be adequately represented in the training set from 
which the nomogram was derived.
A nomogram for obtaining survival estimates for IDH-
wild-type patients with newly diagnosed GBM has been 
developed and independently validated. This tool provides 
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Fig. 3 Calibration curves for training data (the Ohio Brain Tumor Study) for predicted (A) 12-, (B) 18-, and (C) 24-month survival and testing data 
(University of California San Francisco) for predicted (D) 12-, (E) 18-, and (F) 24-month survival for isocitrate dehydrogenase-wild-type newly 
diagnosed glioblastoma patients, 2007–2017.
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an individualized estimate of survival, rather than a group 
estimate based on specific patient-level characteristics, 
which should be useful to patients and healthcare providers 
for counseling patients and their families regarding treat-
ment decisions, follow-up, and prognosis. To facilitate the 
clinical use of this nomogram, free software for its im-
plementation is provided (https://gcioffi.shinyapps.io/
Nomogram_For_IDH_Wildtype_GBM_H_Gittleman/).
Supplementary Material
Supplementary data are available at Neuro-Oncology 
Advances online.
Keywords
glioblastoma | IDH-wild-type | nomogram | survival.
Funding
P.C., A.M.M., and M.S.B. are supported by the UCSF Brain Tumor 
SPORE grant NIH/NCI P50CA097257. A.E.S.  is supported by 
National Institutes of Health CA217956, the Peter D Cristal Chair 
and the Center of Excellence for Translational Neuro-Oncology, 
and the Gerald Kaufman Fund for Glioma Research, the Kimble 
Family Foundation, and the Ferry Family Foundation at University 
Hospitals of Cleveland.
Conflict of interest statement. There are no conflicts of in-
terest to report.
Authorship statement: Study design, data collec-
tion, data analysis/interpretation, figure preparation, 
manuscript drafting, reviewing/editing manuscript: 
Haley Gittleman, Jill S.  Barnholtz-Sloan. Data analysis/in-
terpretation, reviewing/editing manuscript: Gino Cioffi. 
Data collection, reviewing/editing manuscript: Pranathi 
Chunduru, Annette Molinaro, Mitchel Berger. Reviewing/
editing manuscript: Andrew Sloan.
References
1. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular 
prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 
2014;23(10):1985–1996.
2. Gaist  D, Hallas  J, Friis  S, Hansen  S, Sørensen  HT. Statin use and 
survival following glioblastoma multiforme. Cancer Epidemiol. 
2014;38(6):722–727.
3. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal 
growth factor receptor and egfrviii in glioblastoma multiforme patients. 
Clin Cancer Res. 2005;11(4):1462–1466.
4. Ostrom  QT, Gittleman  H, Truitt  G, Boscia  A, Kruchko  C, Barnholtz-
Sloan  JS. CBTRUS statistical report: primary brain and other central 
nervous system tumors diagnosed in the United States in 2011–2015. 
Neuro Oncol. 2018;20(suppl_4):iv1–iv86.
5. Schiffgens  S, Wilkens  L, Brandes  AA, et  al. Sex-specific 
clinicopathological significance of novel (frizzled-7) and estab-
lished (MGMT, IDH1) biomarkers in glioblastoma. Oncotarget. 
2016;7(34):55169–55180.
6. Hanif  F, Muzaffar  K, Perveen  K, Malhi  SM, Simjee  ShU. Glioblastoma 
multiforme: a review of its epidemiology and pathogenesis through clin-
ical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9.
7. McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, et al. Associations be-
tween polymorphisms in DNA repair genes and glioblastoma. Cancer 
Epidemiol Biomarkers Prev. 2009;18(4):1118–1126.
8. Verhaak  RG, Hoadley  KA, Purdom  E, et  al.; Cancer Genome Atlas 
Research Network. Integrated genomic analysis identifies clinically 
relevant subtypes of glioblastoma characterized by abnormalities in 
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.
9. Johnson  DR, O’Neill  BP. Glioblastoma survival in the united 
states before and during the temozolomide era. J Neurooncol. 
2012;107(2):359–364.
10. Kickingereder P, Neuberger U, Bonekamp D, et al. Radiomic subtyping 
improves disease stratification beyond key molecular, clinical, and 
standard imaging characteristics in patients with glioblastoma. Neuro 
Oncol. 2018;20(6):848–857.
11. Stupp R, Mason WP, van den Bent MJ, et al.; European Organisation 
for Research and Treatment of Cancer Brain Tumor and Radiotherapy 
Groups; National Cancer Institute of Canada Clinical Trials Group. 
Radiotherapy plus concomitant and adjuvant temozolomide for glioblas-
toma. N Engl J Med. 2005;352(10):987–996.
12. Preusser M, de Ribaupierre S, Wöhrer A, et  al. Current concepts and 
management of glioblastoma. Ann Neurol. 2011;70(1):9–21.
13. Nafe R, Franz K, Schlote W, Schneider B. Morphology of tumor cell nuclei 
is significantly related with survival time of patients with glioblastomas. 
Clin Cancer Res. 2005;11(6):2141–2148.
14. Song W, Ruder AM, Hu L, et al. Genetic epidemiology of glioblastoma 
multiforme: confirmatory and new findings from analyses of human leu-
kocyte antigen alleles and motifs. PLoS One. 2009;4(9):e7157.
15. Zinn PO, Colen RR, Kasper EM, Burkhardt JK. Extent of resection and ra-
diotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end 
results analysis of 21,783 patients. Int J Oncol. 2013;42(3):929–934.
16. Darefsky AS, King JT Jr, Dubrow R. Adult glioblastoma multiforme survival 
in the temozolomide era: a population-based analysis of surveillance, ep-
idemiology, and end results registries. Cancer. 2012;118(8):2163–2172.
17. Thumma SR, Fairbanks RK, Lamoreaux WT, et al. Effect of pretreatment 
clinical factors on overall survival in glioblastoma multiforme: a surveil-
lance epidemiology and end results (SEER) population analysis. World J 
Surg Oncol. 2012;10:75.
18. Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organi-
zation classification of tumors of the central nervous system: a summary. 
Acta Neuropathol. 2016;131(6):803–820.
19. Stupp  R, Brada  M, van  den  Bent  MJ, Tonn  JC, Pentheroudakis  G; 
ESMO Guidelines Working Group. High-grade glioma: ESMO Clinical 
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 
2014;25(suppl 3):iii93–101.
20. Ceccarelli  M, Barthel  FP, Malta  TM, et  al.; TCGA Research Network. 
Molecular profiling reveals biologically discrete subsets and pathways 
of progression in diffuse glioma. Cell. 2016;164(3):550–563.
9Gittleman et al. Nomogram for survival estimation for IDH-wild-type GBM patients
N
eu
ro-O
n
colog
y 
A
d
van
ces
21. Burton E, Ugiliweneza B, Woo S, Skirboll S, Boaky M. A surveillance, 
epidemiology and end results-medicare data analysis of elderly patients 
with glioblastoma multiforme: treatment patterns, outcomes and cost. 
Mol Clin Oncol. 2015;3(5):971–978.
22. Gittleman H, Lim D, Kattan MW, et al. An independently validated nom-
ogram for individualized estimation of survival among patients with 
newly diagnosed glioblastoma: NRG oncology RTOG 0525 and 0825. 
Neuro Oncol. 2017;19(5):669–677.
23. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting 
survival of patients with newly diagnosed glioblastoma: prognostic 
factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet 
Oncol. 2008;9(1):29–38.
24. Stef van Buuren, Karin Groothuis-Oudshoorn (2011). mice: Multivariate 
Imputation by Chained Equations in R. J Stat Softw, 45(3):1–67. URL 
https://www.jstatsoft.org/v45/i03/.
25. Therneau T (2015). _A Package for Survival Analysis in S_. version 2.38, 
URL: https://CRAN.R-project.org/package=survival.
26. Ishwaran H. and Kogalur UB. (2019). Fast Unified Random Forests for 
Survival, Regression, and Classification (RF-SRC), R package version 
2.9.0.
27. Terry Therneau and Beth Atkinson (2018). rpart: Recursive Partitioning 
and Regression Trees. R package version 4.1–13. https://CRAN.R-
project.org/package=rpart.
28. Grambsch  PM and Therneau  TM. Proportional hazards tests and 
diagnostics based on weighted residuals. Biometrika. 1994; 
81(3):515–526.
29. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues 
in developing models, evaluating assumptions and adequacy, and meas-
uring and reducing errors. Stat Med. 1996;15(4):361–387.
30. Harrell  FE Jr (2018). rms: Regression Modeling Strategies. R package 
version 5.1-2. https://CRAN.R-project.org/package=rms.
31. R Core Team (2018). R: A  Language and Environment for Statistical 
Computing. Vienna, Austria: R Foundation for Statistical Computing. URL 
https://www.R-project.org/.
